Bruton tyrosine kinase inhibitors, or BTKi for short, are by no means new. They are known from cancer therapy and have been adapted for the treatment of neurologically degenerative diseases. So, will there soon be a new class of active substances for Multiple Sclerosis? Numerous studies are underway. What is particularly interesting is their potential use in the progressive courses of Multiple Sclerosis.
Prof. Mathias Mäurer explains in this video what BTKi are, for whom the class of active substances should be used and when the first substances – assuming positive Phase 3 studies – could be approved in Germany. Most recently, Mäurer reported in detail about the “Brutinibs” in 2020.
Please consider using the automated translation of YouTube. You can activate this function by clicking on the settings symbol and choosing subtitles.
